Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 671 of 5804
-
New NanoKnife treatment shows promise for prostate cancer
Disease control CompletedPivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
Phase: NA • Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to halt tough prostate cancer
Disease control Recruiting nowThis phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes need…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Phase: PHASE2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a nanoparticle vaccine stop the virus behind mono and some cancers?
⭐️ VACCINE ⭐️ CompletedBackground: Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Up to 1 in 10 people who get mono can have fatigue that lasts more than 6 months. One out of 100 people can have severe complications. EBV is also associated with several types of cancer. …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Magic mushroom compound shows promise for Hard-to-Treat depression and suicidal thoughts
Symptom relief CompletedThis study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
Phase: PHASE2 • Sponsor: Sheppard Pratt Health System • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Blood test could spot lung cancer return risk after surgery
Disease control Recruiting nowThis is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cocktail of drugs shows promise for nasopharyngeal cancer
Disease control Recruiting nowThe investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabi…
Phase: PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill could cut blood transfusions for blood disorders
Disease control CompletedThis clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
Phase: PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Promising drug may slow blindness in teens with rare eye disease
Disease control CompletedThe primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
Phase: PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New kidney drug could help kids with protein leak
Disease control Recruiting nowResearchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form ur…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New stroke device aims to restore blood flow in distal brain clots
Disease control OngoingThe objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabli…
Phase: NA • Sponsor: Rapid Medical • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New test may predict which breast cancer patients benefit from targeted drug
Disease control CompletedThe primary objetive is to assess the capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1). The investigators propose the hypothesis that the RAD51-foci low tumours determined by immunofluorescen…
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cutting tool may outperform heat therapy for Barrett's esophagus
Disease control Recruiting nowBarrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of adenocarcinoma on BE is 0.5% per year. In the event of dysplasia or cancer in situ, it is currently recommen…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to fight bladder cancer without surgery
Disease control Recruiting nowDURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).
Phase: PHASE1, PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radioactive drug aims to fight gut tumors that resist standard therapy
Disease control Recruiting nowThis study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, w…
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New meningitis vaccine shows promise for infants in phase 3 trial
⭐️ VACCINE ⭐️ CompletedInfants aged 9 months will be randomized to receive a meningococcal vaccine at 9 months or 15 months. Infants randomized to the 9-month age group will be further randomized in a 2:1 ratio to receive a single dose of the experimental meningococcal vaccine (NmCV-5) or a single dose…
Phase: PHASE3 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:02 UTC
-
Blood test may help some throat cancer patients skip or shorten radiation
Disease control Recruiting nowThis study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery. In Arm A the researchers …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo targets Hard-to-Treat nasopharyngeal cancer
Disease control OngoingRecurrence rate after curative treatment for locally advanced Nasopharyngeal carcinoma (NPC) is reported varying from 15% to 30% of cases, while approximately 5-11% of patients present with de novo metastatic disease. In NPC, the immunogenicity of the cancer cell is derived from…
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New chemo cocktail aims to make inoperable stomach cancer removable
Disease control Recruiting nowGastric cancer is the fifth most common carcinoma in the world, and cancer-related deaths rank third. It is one of the main causes of death from cancer in Korea. The cure method for gastric cancer is radical resection, but in most patients, radical resection is impossible due to …
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to shrink Hard-to-Treat breast tumors
Disease control OngoingThis trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior s…
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC